Lund, Sweden, 6 March, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at Leerink Global Healthcare Conference in Miami, at 13:40 PM EDT on Monday 9 March, 2026. Hansa Biopharma COO and President U.S. Maria Törnsén, and CMO Richard Philipson will […]
PDUFA action date for Hansa Biopharma’s imlifidase BLA set for December 19, 2026 Hansa Biopharma announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 📺Optimum TV […]
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. Lund, Sweden, 4 March 2026. Hansa Biopharma AB, (“Hansa” or “the Company”), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been […]
Novo Nordisk Foundation announced it had awarded DKK 11.8 billion (€1.6 billion) during 2025 to support more than 2,200 projects aimed at improving people’s health and the sustainability of society and the planet. The projects cover the full range of the Foundation’s grant-giving areas, including key topics such as cardiometabolic diseases, antimicrobial resistance, the development of more resilient and climate-friendly […]
Lund, Sweden, 23 February, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will be presenting at TD Cowen’s 46th Annual Health Care Conference in Boston, at 11:10-11:40 AM EST on Monday 2 March, 2026. Hansa Biopharma CFO Evan Ballantyne, and COO and President U.S. Maria Törnsén, will […]
